Retinal Imaging

Retinal thickness in Alzheimer’s disease: A systematic review and meta-analysis

Jurre den Haan a,*, Frank D. Verbraak b, c, Pieter Jelle Visser a, d, Femke H. Bouwman a

a Neurology, VU University Medical Center Alzheimer Center, Amsterdam, The Netherlands
b Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
c Ophthalmology Department, VU University Medical Center, Amsterdam, The Netherlands
d Alzheimer Centre, School for Mental Health and Neuroscience (MHeNS), University Medical Centre, Maastricht, The Netherlands

Abstract

Introduction: Retinal characteristics are increasingly recognized as biomarkers for neurodegenerative diseases. Retinal thickness measured by optical coherence tomography may reflect the presence of Alzheimer’s disease (AD). We performed a meta-analysis on retinal thickness in AD and mild cognitive impairment (MCI) patients and healthy controls (HCs).

Methods: We selected 25 studies with measurements of retinal thickness including 887 AD patients, 216 MCI patients, and 864 HCs that measured retinal thickness. Outcomes were peripapillary retinal nerve fiber layer (RNFL) and macular thickness. The main outcome was the standardized mean differences (SMDs). We used STATA to perform the meta-analysis (StataCorp, Texas; version 14.0).

Results: Relative to HCs, AD and MCI patients had lower peripapillary RNFL (SMD 0.98 [CI 1.30, −0.66, P < .0001] and SMD 0.71 [CI −1.24, −0.19, P = .008]). Total macular thickness was decreased in AD patients (SMD 0.88 [CI −1.12, −0.65, P = .0001]).

Discussion: Retinal thickness is decreased in AD and MCI patients compared to HC. This confirms that neurodegenerative diseases may be reflected by retinal changes.

© 2017 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Keywords: Meta-analysis; Optical coherence tomography (OCT); Retinal thickness; Eye; Biomarkers; Alzheimer’s disease (AD); Mild cognitive impairment (MCI)

1. Introduction

Alzheimer’s disease (AD) is the most common form of dementia. It is neuropathologically characterized by amyloid-beta (Aβ)-plaques and neurofibrillary tangles containing tau. These neuropathological changes are believed to develop 15–20 years before symptom onset. AD is diagnosed in subjects with MCI or dementia using clinical criteria combined with abnormal biomarkers for Aβ pathology or neuronal injury [1,2]. Aβ pathology is reflected by decreased Aβ levels in cerebrospinal fluid (CSF) or on an amyloid positron emission tomography (PET). Neuronal injury is reflected by either cortical atrophy on magnetic resonance imaging (MRI), hypometabolism on fluorodeoxyglucose-PET (FDG-PET), or increased tau and/or phosphorylated tau (pTau) levels in CSF [3]. These biomarkers however, are invasive, expensive, or time consuming. Thus, there is an urgent need for an early, patient-friendly, inexpensive AD biomarker, that preferably detects AD pathology before severe neurodegeneration [4].

The retina is embryologically derived from the cranial part of the neural tube, similar to the brain, and therefore shares many similarities with its tissue. The retina is easily accessible, and retinal neurons can be visualized through high-resolution optical methods such as optical coherence tomography (OCT) visualizing thickness of retinal layers (Fig. 1). With OCT, retinal changes are visualized both in ophthalmological disease and in neurodegenerative disease. Previous studies have shown that the retinal nerve fiber layer (RNFL) thickness and ganglion cell layer (GCL) thickness
are reduced in subjects with multiple sclerosis (MS) [5], Parkinson disease (PD) [6], and AD [7–31].

In this study, we perform a meta-analysis to assess the retinal layer thickness in AD and MCI patients and cognitively normal subjects. OCT is an optical method that accurately measures retinal layer thickness and therefore potentially a patient-friendly noninvasive method for detection of neurodegenerative diseases. We also assess the role of concomitant ophthalmological disease on retinal thickness, in particular glaucoma and the possible confounding role of age and disease severity.

2. Methods

2.1. Search strategy

We searched PubMed and EMBASE for studies analyzing OCT measurements in AD patients, MCI patients, and/or healthy controls (HCs) using the following search terms: “Alzheimer’s Disease,” “senile dementia,” “Mild Cognitive Impairment,” “MCI,” “optical coherence tomography,” and “OCT” between 1990 and February 2016.

2.2. Inclusion

We included 25 studies that used NINCDS-ADRDA and/or DSMIV criteria for AD diagnosis, Petersen or Winblad criteria for MCI, and OCT to assess retinal layer thickness. Eight of these studies included an MCI group. Ten studies used first-generation time domain (TD)-OCT, and 15 studies used spectral domain (SD)-OCT. Twenty-four studies performed a peripapillary RNFL protocol (of which 16 studies presented data for separate quadrants). One study performed a macular protocol only, and six studies performed both a peripapillary and macular protocol. Eight studies included neuroimaging (MRI or CT), and two studies included CSF analysis (Table 1 characteristics of the included studies).

Of the 637 records identified, 612 were excluded due to their title, topic, method, or design. Others were excluded due to their abstracts, reviews, posters, communications in response to an article, or in the case of duplicate data. Studies with nondemented subjects or studies that use different techniques such as RNFL thickness with Heidelberg Retinal Tomography (HRT), fundus autofluorescence, and electroretinography were also excluded (Fig. 2 flowchart of included and excluded articles).

2.3. Data extraction

We extracted mean and quadrant RNFL and macular thickness with standard deviations for AD and MCI patients
and HC. In one study, data were presented as box plots [25]. Estimates of the mean and standard deviation were therefore calculated using the lower and upper quartiles, mean, and sample size following the methods described in Wan et al. [32]. A second study described RNFL thickness in bar diagrams without exact figures [27]. RNFL thickness means and standard deviations were therefore estimated with the help of the measure tool in Adobe Acrobat XI Pro (version 11.0.0). The standard errors were calculated to standard deviations.

2.4. Outcome measures

Peripapillary RNFL thickness was presented in superior, inferior, temporal, nasal, and mean quadrants. Total macular thickness was subdivided according to the Early Treatment Diabetic Retinopathy Study regions: fovea, inner and outer ring.

2.5. Study quality rating

The QUADAS tool was used to assess the methodological quality for each study by two authors (J.d.H. and F.D.V.) (Supplementary Table 1) [33].

Glaucoma is an important potential confounder as it is a neurodegenerative disease of the retina resulting in RNFL loss. We therefore reviewed whether glaucoma was assessed by (1) medical history, (2) intraocular pressure, (3) biomicroscopy, (4) fundus photographs, and/or (5) functional assessment in the form of visual field defects to generate a glaucoma exclusion score. All studies used ophthalmological history and intraocular pressure for the exclusion of glaucoma. However, this may not detect all cases, in particular normal tension glaucoma. Therefore, we totaled the number of additional assessments performed for exclusion of glaucoma: (1) posterior segment biomicroscopy, (2) fundus photographs, and/or (3) functional assessment (visual fields). The higher the resulting glaucoma exclusion

| Study | Year | Scanner type | Protocols used | OCT* Subjects | MMSE | Age |
|-------|------|--------------|----------------|---------------|------|-----|
|       |      |              |                |                  |      |     |
| 1     | 2016 | Cirrus 4000 HDOCT | Peripapillary RNFL | 21 | 20 | 34 | - | - | 65.80 | 65.10 |
| 2     | 2016 | Stratus OCT3 | Peripapillary RNFL | 21 | - | 74 | 18.3 | - | 71.20 | 69.10 |
| 3     | 2015 | OCT1000 Topcon | Peripapillary RNFL | 23 | - | 28 | 23.3 | 28.2 | 79.30 | 72.30 |
| 4     | 2015 | RTVue 100 Fourier-domain | Peripapillary RNFL | 18 | - | 20 | - | - | 73.60 | 73.30 |
| 5     | 2015 | OPKO/OTI SD-OCT | Peripapillary RNFL | 20 | - | 20 | - | - | 75.02 | 74.15 |
| 6     | 2015 | Stratus OCT3 | Peripapillary RNFL | 67 | 26 | 39 | - | - | 71.35 | 69.70 |
| 7     | 2015 | Cirrus HDOCT | Peripapillary RNFL | 35 | 35 | 35 | 18 | 29 | 75.40 | 70.20 |
| 8     | 2015 | Cirrus HDOCT | Peripapillary RNFL | 100 | 41 | 123 | - | - | 73.50 | 65.70 |
| 9     | 2015 | Cirrus HDOCT | Peripapillary RNFL | 25 | 26 | 21 | 19.24 | 28.57 | 74.72 | 72.05 |
| 10    | 2015 | Cirrus HDOCT | Peripapillary RNFL | 56 | - | 56 | 16.56 | - | 74.00 | 76.40 |
| 11    | 2014 | Cirrus HDOCT | Peripapillary RNFL | 151 | - | 61 | 18.31 | - | 75.29 | 74.87 |
| 12    | 2014 | Stratus OCT3 | Macular thickness | 18 | 21 | 41 | 19.31 | 28.78 | 72.10 | 72.90 |
| 13    | 2014 | Cirrus HDOCT | Macular thickness | 70 | - | 70 | 15.96 | - | 74.15 | 73.98 |
| 14    | 2014 | Heidelberg Spectralis | Peripapillary RNFL | 21 | - | 21 | 22.2 | 28.2 | 73.10 | 70.30 |
| 15    | 2014 | Heidelberg Spectralis | Peripapillary RNFL | 22 | - | 22 | 22.59 | - | 75.90 | 64.00 |
| 16    | 2013 | OCT1000 Topcon | Peripapillary RNFL | 10 | - | 10 | 16.4 | 29.2 | 73.00 | 70.20 |
| 17    | 2013 | RTVue | Macular thickness | 21 | - | 21 | - | - | 79.30 | 77.00 |
| 18    | 2013 | OCT1000 Topcon | Peripapillary RNFL | 40 | - | 40 | 18–25 | - | 69.30 | 68.90 |
| 19    | 2012 | Stratus OCT3 | Peripapillary RNFL | 30 | - | 30 | - | - | 71.77 | - |
| 20    | 2011 | Stratus OCT3 | Peripapillary RNFL | 30 | 24 | 24 | 23.6 | - | 73.70 | 70.90 |
| 21    | 2010 | Stratus OCT3 | Peripapillary RNFL | 22 | - | 22 | - | - | 73.00 | 68.00 |
| 22    | 2007 | Stratus OCT3 | Peripapillary RNFL | 26 | 23 | 15 | 19.8 | 28.9 | 78.83 | 75.50 |
| 23    | 2007 | Stratus OCT3 | Peripapillary RNFL | 9 | - | 8 | 23.8 | 29.5 | 74.30 | 74.30 |
| 24    | 2006 | Stratus OCT3 | Peripapillary RNFL | 14 | - | 15 | 18.5 | 29.4 | 70.10 | 65.10 |
| 25    | 2001 | Stratus OCT3 | Peripapillary RNFL | 17 | - | 14 | 16.38 | 23 | 70.37 | - |

Abbreviations: OCT, optical coherence tomography; MMSE, Mini–Mental State Examination; AD, Alzheimer’s disease; MCI, mild cognitive impairment; HC, healthy control; RNFL, retinal nerve fiber layer.

*First-generation (time domain) OCT scanner is the stratus OCT3 and second-generation (spectral domain) OCT scanners are the Cirrus HDOCT, Heidelberg Spectralis, OPKO/OTI, OCT1000 Topcon, and RTVue.
score, the more stringent the exclusion criteria for glaucoma were met (Supplementary Table 2).

2.6. Statistical analysis

We used random-effects models for the meta-analysis with a main outcome measure of Cohen’s d (standardized mean difference [SMD]). Heterogeneity was assessed by $\chi^2$ test, and Egger’s regression test was used to test funnel plot asymmetry. A funnel plot was generated to assess publication bias and was statistically tested with Begg’s and Egger’s tests. We used STATA (StataCorp, Texas; version 14.0) for all analyses, with the metan command to create forest plots, the metabias command for funnel plot, and the metareg command to perform meta-regression.

Both univariate meta-regression and multivariate meta-regression were used to assess whether study characteristics were associated with the SMD. Meta-regression was carried out with the SMD as a dependent variable. Independent variables were as follows: OCT type (TD vs. SD), mean study Mini–Mental State Examination (MMSE) in the AD group, study glaucoma exclusion score, and mean study age. We performed subgroup analysis for first- and second-generation OCT scanner type (TD-OCT and SD-OCT, respectively) and for the four (superior, inferior, nasal, and temporal) peripapillary quadrants.

3. Results

3.1. Peripapillary retinal nerve fiber layer thickness

Mean peripapillary RNFL was described in 24 studies including 887 AD patients and 864 HCs. RNFL thickness was lower in AD versus HC (SMD $-0.98$ [CI $-1.30$, $-0.66$, $P = .000$], which corresponds to an absolute decrease of $9.70 \mu$m (CI $-10.76$, $-8.6$, $P = .000$) (Fig. 3A). Fig. 3B and C show a larger effect for the TD than the SD scanner type, with effect estimates of respectively $-1.38$ (CI $-1.91$, $-0.86$, $P = .000$) and $-0.70$ (CI $-1.07$, $-0.33$, $P = .000$). Table 2 shows the differences between AD and
HC for the mean peripapillary RNFL thickness and in the four quadrants in 20 studies. The superior and inferior quadrants are thinner than the nasal and temporal quadrants.

Eight studies measured peripapillary RNFL thickness including a MCI group consisting of 322 AD patients, 216 MCI patients, and 367 HCs and measured peripapillary RNFL thickness. RNFL thickness of the MCI group was between the RNFL thickness of AD patients and HC, with a standardized mean difference of 2.0.71 (CI 2.1.24, 2.0.19, P = .008) compared to controls and of 2.0.43 (CI 2.0.73, 2.0.13, P = .005) in comparison with AD patients.

### 3.2. Macular thickness

Seven studies described macular thickness of 302 AD patients in total and 241 HCs, showing significant thinning in the fovea, inner ring, and outer ring. Effect estimates are displayed in these three macular regions showing the largest effect on the outer ring −0.88 (CI −1.12, −0.65, P = .000), followed by the inner ring (−0.77 [CI −0.96, −0.59] P = .000) and fovea (−0.37 [CI −0.65, −0.09], P = .010) (Fig. 4).

### 3.3. Meta-regression

Meta-regression shows that OCT type, mean study MMSE score, glaucoma exclusion score, and mean study age are not associated with the SMD in the AD group compared to HC.

### 3.4. Publication bias

The funnel plot is relatively asymmetrical and indicates publication bias (Supplementary Fig. 1).

### 4. Discussion

We performed a systematic review and comprehensive meta-analysis to assess differences in retinal layer thickness between AD and MCI patients and HCs. We show that both mean peripapillary RNFL and macular thickness decreased in AD patients compared to HCs. The difference in thickness is more apparent with TD scanners than the now widely used SD-OCT. This presents an interesting finding because the resolution (5 μm vs. 10 μm) and acquisition time of the currently used SD-OCT are superior to TD-OCT and

![Fig. 3. Mean peripapillary RNFL in AD and HC. Forest plots of standardized mean peripapillary retinal nerve fiber layer (RNFL) in (A) all studies (n = 24), (B) studies with time domain (TD)-OCT scanners (n = 10), and (C) spectral domain (SD)-OCT studies (n = 14). Abbreviations: AD, Alzheimer’s disease; HC, healthy control; OCT, optical coherence tomography.](image-url)

| Peripapillary RNFL in all quadrants (n = 20 studies) |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|
| AD versus HC                    | Superior        | Inferior        | Nasal           | Temporal        |
| Mean                            | −0.95 [−1.29, −0.61] | −0.99 [−1.34, −0.65] | −0.81 [−1.13, −0.49] | −0.57 [−0.83, −0.30] | −0.42 [−0.63, −0.20] |

Abbreviations: AD, Alzheimer’s disease; HC, healthy control; RNFL, retinal nerve fiber layer.

NOTE: All P < .000.

NOTE: Standardized mean differences of peripapillary RNFL between study groups in all quadrants.
currently used by most clinicians. However, fewer artifacts and significantly higher retinal thickness in SD-OCT with higher resolution compared to TD-OCT were reported before, and this may be an explanation for these differences [34].

The MCI group was in between AD and HC. As the differences are small, however, application of retinal thickness measurements as a diagnostic biomarker in the individual patient is challenging.

We found peripapillary RNFL thickness to be lower in the superior and inferior quadrants than in nasal and temporal quadrants. This may be related to the fact that the superior and inferior quadrants contain more neurons, and therefore, neurodegeneration is expected to be most prominent. Similarly, we would expect a more prominent change in the thicker GCL in the inner ring of the macula.

In contrast, macular thickness displays the most prominent decrease in the outer ring, which may reflect RNFL loss in the periphery.

Retinal thinning is associated not only with AD but also with glaucoma. Glaucoma is a chronic, age-related, and neurodegenerative disease affecting the RNFL and hypothesized to share a common pathophysiology (neuroinflammation, lower Aβ in CSF [35] and vitreous humor [36], and retinal ganglion cell death [37]). In addition, the prevalence of glaucoma is increased in AD patients; 25.9 %, compared to 1%–5.2% in the normal population [38–40]. The reverse correlation is less distinct as some population studies of glaucoma patients show a higher risk of AD [41], whereas others reported no association [42,43]. Possibly, AD is a risk factor for glaucoma, or AD and glaucoma share a pathophysiological process with retinal neurodegeneration as final common pathway. Two recent studies of Eraslan et al. and Cesareo et al., measuring RNFL with OCT, visual field defects with frequency doubling technology, and optic nerve head morphology with HRT, showed similar patterns of RNFL thinning, visual field loss, and optic nerve head morphology in AD and normal tension glaucoma [10,44]. Consequently, it seems very challenging to discriminate retinal changes due to AD from retinal changes due to glaucoma. Therefore, stressing the need to account for glaucoma as a contributor to retinal thickness decreases.

The strengths of our meta-analysis are the inclusion of a large number of AD and MCI patient cohorts and HCs, as well as assessment of both peripapillary and macular thinning. In addition, we addressed scanner difference and the influence of glaucoma as a possible confounder.

Among limitations are the studies used showed heterogeneity in the meta-regression that could not be attributed to scanner type, MMSE, and/or age. Another limitation is that AD diagnosis in the included studies was based on clinical criteria without the support of biomarkers. The National Institute on Ageing–Alzheimer’s Association (NIA-AA) criteria suggest incorporating the use of biomarkers reflecting AD pathology for an accurate diagnosis [2]. In this respect, it is important to realize that several amyloid PET studies showed that around 20% of clinically diagnosed AD patients have a normal amyloid PET scan, leading to a change in clinical diagnosis [45]. A third limitation is that
we did not have sufficient data to compare retinal thickness in other neurodegenerative diseases. We found only one study with data on PD and dementia with Lewy bodies (DLB), showing retinal thinning in PD and DLB. A fourth limitation is revealed by the funnel plot asymmetry and statistical tests, indicating publication bias, with an overrepresentation of smaller positive studies. Study results may thus be an overestimation of the true effect.

Segmentation software recently became available to section retinal layers for assessment of change in individual retinal layers. With this method, a loss of GCL was demonstrated in patients with diabetes mellitus type II for example, without signs of vasculopathy, in the inner ring, reflecting neuroretinal degeneration [46]. A recent study of Salobrar-Garcia et al. used segmentation analysis in AD and mainly showed a contribution of inner retinal layers, GCL, RNFL, and inner plexiform layer (IPL) [9]. Interestingly, they found a decrease in macular thickness while peripapillary thickness was unchanged, suggesting macular before peripapillary degeneration. In contrast, an increase of IPL thickness was reported in a recent study of Snyder et al. in preclinical AD [47]. Future research may use segmentation to identify the alterations of specific retinal layers in AD and its preclinical and prodromal stages.

As shown before and in this meta-analysis, group differences in RNFL and macular thickness are small, limiting clinical application as a biomarker. When comparing these group differences with widely used MRI biomarkers, however, retinal neurodegeneration shows a comparable group difference to visual rating scores such as medial temporal lobe atrophy (1.1–1.79 SD) [48–50]. To assess the diagnostic value of OCT, comparison with the current gold standard, NIA-AA criteria–based diagnosis with the use of biomarkers (e.g., amyloid PET, CSF, and/or FDG-PET) is necessary to determine sensitivity and specificity of OCT.

5. Conclusion
We found that the peripapillary RNFL and macular thickness are significantly decreased in AD patients compared to HC. In addition, we took glaucoma into account as a potential confounder, that possibly overestimated the effect of AD on retinal thickness in the described studies. As of yet OCT cannot yet be applied as a diagnostic biomarker for AD in clinical practice.

Future research should focus on OCT measurements in a well-described cohort of preclinical, prodromal (i.e., MCI) and demented AD patients and subjects with information on amyloid status (positive or negative). Segmentation of individual retinal layers may provide insight into the pathophysiology of retinal neurodegeneration in AD. Correlating OCT measurements with other biomarkers of neuronal injury (i.e., hippocampal atrophy on MRI, hypometabolism on FDG-PET, or increased CSF tau and pTau levels) may give new insight in OCT measurements as biomarker of neurodegeneration.

Acknowledgments
F.D.V., P.J.V., F.H.B., and corresponding author J.d.H. report no disclosures. This study is not industry sponsored. J.d.H. contributed to the study concept and design, acquisition of data, analysis, and interpretation. F.D.V. contributed to the meta-analysis inclusive of all the studies has been considered.

Supplementary data
Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.dadm.2016.12.014.

RESEARCH IN CONTEXT

1. Systematic review: The use of optical coherence tomography (OCT) to assess retinal layer thickness has expanded from ophthalmology to neurodegenerative diseases, in specific Alzheimer’s disease. The authors reviewed the literature for studies performing OCT in AD patients, MCI patients and controls and no meta-analysis inclusive of all the studies has been considered.

2. Interpretation: Our meta-analysis shows that retinal neurodegeneration is present in AD and MCI patients and might therefore mirror brain pathology. However, changes are small, which might hamper use as a diagnostic biomarker.

3. Future direction: Studies assessing OCT measurements together with neuropsychological assessment, MRI, CSF, and PET biomarkers should be conducted to assess its role as a diagnostic biomarker. In addition, more specific retinal biomarkers (e.g., retinal amyloid) might aid early noninvasive diagnosis and disease monitoring before severe neurodegeneration is present.

References
[1] Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7:280–92.
[2] McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s
Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7:263–9.
[3] Jack CR, Holtzman DM. Biomarker modeling of Alzheimer’s disease. Neuron 2013;80:1347–58.
[4] Reardon S. Antibody drugs for Alzheimer’s show glimmers of promise. Nature 2015;523:509–10.
[5] Petzold A, de Boer JF, Schippling S, Verbiersch P, Kardon R, Green A, et al. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol 2010;9:921–32.
[6] Yu JG, Feng YF, Xiang Y, Huang JH, Savini G, Parisi V, et al. Retinal nerve fiber layer thickness changes in Parkinson disease: a meta-analysis. PLoS One 2014;9:e85718.
[7] Pillai JA, Bemmel J, Bonner-Jackson A, Rae-Grant A, Fernandez H, Bena J, et al. Retinal nerve fiber layer thinning in Alzheimer’s disease: a case-control study in comparison to normal aging, Parkinson’s disease, and non-Alzheimer’s disease. Am J Alzheimers Dis Other Demen 2016;31:430–6.
[8] La Morgia C, Ross-Cisneros FN, Koronyo Y, Hannibal J, Gallassi R, Cantalupo G, et al. Melanopsin retinal ganglion cell loss in Alzheimer’s disease. Ann Neurol 2016;79:90–109.
[9] Salobrar-Garcia E, Hoyas I, Leal M, de Hoz R, Rojas B, Ramirez AI, et al. Analysis of retinal peripapillary atrophy in early Alzheimer’s disease patients. Biomed Res Int 2015;2015:636548.
[10] Eraslan M, Çerman E, Çekiç O, Balcı S, Dericioğlu V, Sahin O, et al. Neurodegeneration in ocular and central nervous systems: optical coherence tomography study in normal-tension glaucoma and Alzheimer disease. Turk J Med Sci 2015;45:1106–14.
[11] Güneş A, Demirci S, Tökö L, Tökö Ö, Demirci S. Evaluation of retinal nerve fiber layer thickness in Alzheimer disease using spectral-domain optical coherence tomography. Turk J Med Sci 2015;45:1094–7.
[12] Liu D, Zhang L, Li Z, Zhang X, Wu Y, Yang H, et al. Thinner changes of the retinal nerve fiber layer in patients with mild cognitive impairment and Alzheimer’s disease. BMC Neurosci 2015;15:1–5.
[13] Oktém EO, Derle E, Kabaroğlu S, Oktém C, Akköylu I, Can U. The relationship between the degree of cognitive impairment and retinal nerve fiber layer thickness. Neurol Sci 2015;36:1141–6.
[14] Cheung CY, Ong YT, Hilal S, Ikram MK, Low S, Ong YL, et al. Retinal ganglion cell analysis using high-definition optical coherence tomography in patients with mild cognitive impairment and Alzheimer’s disease. J Alzheimers Dis 2015;45:45–56.
[15] Gao L, Liu Y, Li X, Bai Q, Liu P. Abnormal retinal nerve fiber layer thickness and macula lutea in patients with mild cognitive impairment and Alzheimer’s disease. Arch Gerontol Geriatr 2015;60:162–7.
[16] Bambo MP, García-Martín E, Gutierrez-Ruiz F, Pinilla J, Perez-Oliván S, Larrosa JM, et al. Analysis of optic disc color changes in Alzheimer’s disease: a potential new biomarker. Clin Neurol Neurosurg 2015;132:68–73.
[17] Larrosa JM, Garcia-Martín E, Bambo MP, Pinilla J, Polo V, Otín S, et al. Potential new diagnostic tool for Alzheimer’s disease using a linear discriminant function for Fourier domain optical coherence tomography. Invest Ophthalmol Vis Sci 2014;55:3043–51.
[18] Ascaso FJ, Cruz N, Modrego PJ, Lopez-Anton R, Santabarbara J, Pascual LF, et al. Retinal alterations in mild cognitive impairment and Alzheimer’s disease: an optical coherence tomography study. J Neuro Eye Dis 2014;26:1522–30.
[19] Polo V, García-Martín E, Bambo MP, Pinilla J, Larrosa JM, Satue M, et al. Reliability and validity of Cirrus and Spectralis optical coherence tomography for detecting retinal atrophy in Alzheimer’s disease. Eye (Lond) 2014;28:680–90.
[20] Gharbiya M, Trebbastoni A, Parisi F, Manganiello S, Cruciani F, D’Antonio F, et al. Choroidal thinning as a new finding in Alzheimer’s disease: Evidence from enhanced depth imaging spectral domain optical coherence tomography. J Alzheimers Dis 2014;40:907–17.
[21] Kroner R, Serbecie N, Hauser L, Froehlich L, Abo-ul-Enine F, Beutelspacher SC. Detection of retinal nerve fiber layer defects in Alzheimer’s disease using SD-OCT. Front Psychiatry 2014;5:22.
[22] Moreno-Ramos T, Benito-Leon J, Villarejo A, Bermejo-Pareja F. Retinal nerve fiber layer thinning in dementia associated with Parkinson’s disease, dementia with Lewy bodies, and Alzheimer’s disease. J Alzheimers Dis 2013;34:659–64.
[23] Marziani E, Pomati S, Ramolfo P, Cigada M, Giani A, Mariani C, et al. Evaluation of retinal nerve fiber layer and ganglion cell layer thickness in Alzheimer’s disease using spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci 2013;54:5953–8.
[24] Kirbas S, Türkylmaz K, Anlar O, Tufekci A, Durmus M. Retinal nerve fiber layer thickness in patients with Alzheimer disease. J Neurophthalmol 2013;33:58–61.
[25] Moschos MM, Markopoulos I, Chatziralli I, Rouvas A, Papageorgiou SG, Ladas I, et al. Structural and functional impairment of the retina and optic nerve in Alzheimer’s disease. Curr Alzheimer Res 2012;9:782–8.
[26] Kesler A, Vakhapova V, Korczyn AD, Naftaliev E, Neudorfer MD. Retinal thickness in patients with mild cognitive impairment and Alzheimer’s disease. Clin Neurol Neurosurg 2011;113:523–6.
[27] La Y, Li Z, Zhang X, Ming B, Jia J, Wang R, et al. Retinal nerve fiber layer structure abnormalities in early Alzheimer’s disease: evidence of optical coherence tomography. Neurosci Lett 2010;480:69–72.
[28] Paquet C, Boissounot M, Roger F, Dighiero P, Gil R, Hugon J, et al. Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer’s disease. Neurosci Lett 2007;420:97–9.
[29] Berisha F, Feke GT, Trempe CL, McMeel JW, Schepens CL. Retinal abnormalities in early Alzheimer’s disease. Invest Ophthalmol Vis Sci 2007;48:2285–9.
[30] Iseri PK, Altinas O, Tokay T, Yuksel N. Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J Neuroophthalmol 2006;26:18–24.
[31] Parisi V, Restuccia R, Fattapposta F, Mina C, Bucci MG, Pierelli F. Morphological and functional retinal impairment in Alzheimer’s disease patients. Clin Neurophysiol 2001;112:1860–7.
[32] Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014;14:135.
[33] Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003;3:25.
[34] Forte R, Cennigliano ML, de Cicchino G. Comparison of time domain Stratus OCT and spectral domain SLO/OCT for assessment of macular thickness and volume. Eye (Lond) 2009;23:2071–8.
[35] Bouwman FH, Schoonenoos NM, Verwey NA, van Elk EJ, Kok A, Blankenstein MA, et al. CSF biomarker levels in early and late onset Alzheimer’s disease. Neurobiol Aging 2009;30:1895–901.
[36] Yoneda S, Hara H, Hirata A, Fukushima M, Inomata Y, Tanihara H. Vitreous fluid levels of beta-amyloid(1–42) and tau in patients with retinal diseases. Jpn J Ophthalmol 2005;49:106–8.
[37] Sadun AA, Bassi CJ. Optic nerve damage in Alzheimer’s disease. Ophthalmology 2000;107:1387–96.
[38] de Wied W, ter Weeten J, Schaper HW, van der Tweel I, Achten J, Brouwer A, et al. Prevalences—The Rotterdam Study. Invest Ophthalmol Vis Sci 2002;43:2164–74.
Lin IC, Wang YH, Wang TJ, Wang JJ, Shen YD, Chi NF, et al. Glaucoma, Alzheimer’s disease, and Parkinson’s disease: an 8-year population-based follow-up study. PLoS One 2014;9:e108938.

Ou Y, Grossman DS, Lee PP, Sloan FA. Glaucoma, Alzheimer disease and other dementia: a longitudinal analysis. Ophthalmic Epidemiol 2012;19:285–92.

Keenan TD, Goldacre R, Goldacre MJ. Associations between primary open angle glaucoma, Alzheimer’s disease and vascular dementia: record linkage study. Br J Ophthalmol 2015;99:524–7.

Cesareo M, Martucci A, Ciuffoletti E, Mancino R, Cerulli A, Sorge RP, et al. Association between Alzheimer’s disease and glaucoma: a study based on Heidelberg retinal tomography and frequency doubling technology perimetry. Front Neurosci 2015;9:479.

van Dijk HW, Verbraak FD, Kok PH, Stehouwer M, Garvin MK, Sonka M, et al. Early neurodegeneration in the retina of type 2 diabetic patients. Invest Ophthalmol Vis Sci 2012;53:2715–9.

Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BN, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA 2015;313:1939–49.

van Dijk HW, Verbraak FD, Kok PH, Stehouwer M, Garvin MK, Sonka M, et al. Early neurodegeneration in the retina of type 2 diabetic patients. Invest Ophthalmol Vis Sci 2012;53:2715–9.

Snyder PJ, Johnson LN, Lim YY, Santos CY, Alber J, Maruff P, et al. Nonvascular retinal imaging markers of preclinical Alzheimer’s disease. Alzheimers Dement (Amst) 2016;4:169–78.

Lehmann M, Koedam EL, Barnes J, Bartlett JW, Barkhof F, Wattjes MP, et al. Visual ratings of atrophy in MCI: prediction of conversion and relationship with CSF biomarkers. Neurobiol Aging 2013;34:73–82.

Clerx L, Visser PJ, Verhey F, Aalten P. New MRI markers for Alzheimer’s disease: a meta-analysis of diffusion tensor imaging and a comparison with medial temporal lobe measurements. J Alzheimers Dis 2012;29:405–29.

van de Pol LA, Hensel A, van der Flier WM, Visser PJ, Pijnenburg YA, Barkhof F, et al. Hippocampal atrophy on MRI in frontotemporal lobar degeneration and Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2006;77:439–42.